HCA

Business profile & competitive position

HCA Healthcare, Inc. sits in the Healthcare sector under the Medical - Care Facilities industry. As of December 31, 2025, the company operated 190 hospitals—179 general acute care, seven behavioral, and four rehabilitation facilities—alongside 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers across 19 U.S. states and England. Its facilities provide inpatient and outpatient medical/surgical care, emergency and diagnostic services, mental health services, and ancillary services through ASCs, urgent/walk-in clinics, physician practices, home health agencies, hospices, and rehabilitation facilities. That footprint gives HCA a scale-driven competitive position: 179 general acute care hospitals alone hold 50,436 licensed beds, and the company’s 121 ASCs extend its reach into higher-margin outpatient settings.

The margin and return data tell a nuanced story. A net margin of 8.8% shows the core acute-care business is profitable, while the P/E of 13.5 suggests the market is not pricing HCA like a high-growth stock. The standout figure is ROE of -112.9%. Paired with a positive net margin, that negative ROE is mechanically consistent with negative book equity—often the result of aggressive share repurchases and leverage rather than operating losses. In hospital operations, local market density and physician alignment are usually the real moat, and HCA’s bed count, ASC network, and concentrated geographic presence in high-population states support that narrative.

Financial posture

HCA carries an $87.7 billion market capitalization and trades at a 13.5x P/E, which is modest compared with many corners of the equity market. Its net margin of 8.8% reflects solid cost control across a complex service mix, and the 14.9% of 2025 revenue tied to Medicare plus the 48.9% from managed care and other insurers means reimbursement pressure from both government and commercial payers is a constant feature, not an afterthought. Beta at 1.11 indicates the stock moves slightly more than the broad market, reasonable for a levered healthcare-services name.

The -112.9% ROE is the figure that jumps off the page. Because ROE is net income divided by shareholders’ equity, a deeply negative reading when net income is positive typically signals common equity has been pushed below zero—commonly through debt-funded buybacks. That makes the company look more leveraged than operationally impaired, though it also raises sensitivity to interest rates and refinancing costs. Overall, HCA’s valuation and profitability metrics paint the picture of a mature, cash-generating healthcare operator rather than a high-multiple growth story.

Strategic priorities & outlook

HCA’s most recent 10-K filing outlines four operational priorities: grow its presence in existing markets; achieve industry-leading performance in clinical, operational, and satisfaction measures; recruit and retain physicians and other health care professionals; and advance its digital and artificial intelligence capabilities. These priorities fit a company that is already large and is now trying to deepen share in existing markets rather than expand broadly into new geographies.

The filing also highlights real operational scale. In 2025, revenue reached $75.6 billion, with nearly half from managed care and other insurers and 14.9% from Medicare. Notably, operations are heavily concentrated in Florida and Texas, so macro, regulatory, competitive, and public health developments in those two states carry outsized weight for the company. The push into AI and digital tools, alongside the new ambulatory operations group announced in August 2026, aligns with a strategy to improve throughput, staffing efficiency, and outpatient throughput—key levers for a business with 50,436 licensed beds and a sprawling ASC network.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, HCA is first and foremost exposed to the U.S. healthcare regulatory and reimbursement environment. Medicare and Medicaid rates, Affordable Care Act policy, site-of-service rules, and surprise-billing regulations all directly affect revenue and profitability. Labor markets for nurses, physicians, and technicians are a structural cost pressure, because wage inflation directly hits a labor-intensive services model. The company’s Florida and Texas concentration adds state-specific regulatory and public-health sensitivity, including Medicaid expansion decisions, certificate-of-need laws, and population-demand trends.

Beyond reimbursement, hospital chains are indirectly exposed to supply-chain and trade dynamics through medical devices, pharmaceuticals, and equipment costs. Currency risk is modest but present because HCA operates in England. Interest rates also matter: with negative book equity and implied leverage, the cost of refinancing debt can influence capital allocation and share-buyback capacity. Unlike a commodity producer, HCA does not face raw-material price swings directly, but the macro backdrop shapes both its cost base and the generosity of its payers.

Recent developments

Recent news flow has been mixed but informative. On August 12, 2026, defenseworld.net reported that Assenagon Asset Management S.A. sold 63,779 shares of HCA. Two days earlier, on August 10, 2026, Deane Retirement Strategies Inc. disclosed a new $4.80 million position. The cross-currents show institutional investors actively repositioning around the name rather than uniformly moving in one direction.

On August 6, 2026, HCA announced two executive moves: Dr. Michael Schlosser was named Executive Vice President and Chief Clinical Officer, and Charles Gressle was appointed President of a new Ambulatory Operations Group. The same day, Pomerantz Law Firm disclosed an investor-alert investigation into HCA, according to prnewswire.com. Executive shifts toward ambulatory operations are consistent with the 10-K emphasis on outpatient and digital growth; the investigation headline is a reminder that litigation and regulatory scrutiny are recurring features for large healthcare providers.

Earnings behavior & post-earnings drift

HCA has been unusually reliable on earnings day. Over the last eight reported quarters, the company beat the consensus estimate every single time, for a 100% beat rate. The average earnings surprise across those eight quarters was 6.4%. That history makes the $6.78 consensus EPS estimate for the next report on October 23, 2026, before the open, the market’s real expectation to watch.

The post-earnings drift has also tilted positive. The average 5-day price move after earnings across the last eight quarters was 1.75%, classified as an “up” drift. Even so, individual quarters show volatility. The most recent report on July 24, 2026, delivered EPS of $7.59 against an estimate of $7.56, a 0.4% surprise, and the stock rose 1.94% the next day and 5.34% over the following five sessions. The April 24, 2026 quarter posted $7.15 versus $7.12 (0.4% surprise), with a 3.09% next-day gain but only a 0.15% five-day drift. January 27, 2026 showed the power of a larger beat: $8.01 versus $7.46 (7.4% surprise), yet the stock fell 2.89% the next day and 1.31% over five days. The October 24, 2025 report produced the largest surprise in this window, $6.96 versus $5.79 (20.2%), driving a 4.66% next-day pop and a 2.83% five-day drift. The overall pattern is one of consistent beats, but the immediate reward for beating can vary sharply depending on forward guidance and tone.

For a deeper dive into how institutional analysts are interpreting HCA’s valuation, leverage profile, and reimbursement risks ahead of the October 23, 2026 earnings report, review the full institutional verdict on the ticker page.